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Most tumors express antigens that can be rec-
ognized by T cells of the host immune system 
(Huang et al., 1994; Boon and Old, 1997). De-
spite the expression of antigens, tumors grow 
progressively and evade immunity. It has gen-
erally been assumed that immune evasion is a 
result of a failure to initiate an antitumor adap-
tive immune response. However, recent results 
have indicated that in many instances, sponta-
neous T cell responses against tumor antigens 
can be detected in both human cancer patients 
and in murine models, and that immune escape 
in those cases appears to occur through domi-
nant inhibition by immunoregulatory pathways 
(Vesely et al., 2011). For example, high fre-
quencies of CD8+ T cells specific for MelanA/
MART-1,  MAGE-10,  and  NY-Eso-1  have 
been detected in the blood of subsets of pa-
tients with metastatic melanoma (Pittet et al., 
1999; Valmori et al., 2001; Mortarini et al., 2003; 
Peterson  et  al.,  2003).  Spontaneous  antibody   
responses against a range of tumor-associated anti-
gens have been previously described (Tan and   
Zhang,  2008).  Antibody  responses  in  early 
stage prostate cancer have been reported to be 
detected before PSA becomes detectably ele-
vated (Wang et al., 2005). Moreover, we and 
others have shown that some human melanoma 
metastases contain activated CD8+ T cells, in-
cluding tumor-reactive cells (Anichini et al., 
1999; Harlin et al., 2009), suggesting that spon-
taneous immune responses can be generated all 
the way through to the step of effector cell   
migration into tumor sites. Expression of multiple 
immune evasion mechanisms likely blunts im-
mune function at the effector phase and allows 
tumor outgrowth in those instances (Rabinovich 
et al., 2007).
The observation that a T cell response can 
ever become spontaneously primed against a 
growing tumor mass raises the question of how 
this is possible given the tight regulation of   
innate immune signals that dictate whether a 
bridge to adaptive immunity can occur. Most 
malignancies (including melanoma) lack an ob-
vious infectious etiology and therefore would 
not contain abundant external ligands for Toll-
like receptors (TLRs). In this context, studies 
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Despite lack of tumor control in many models, spontaneous T cell priming occurs frequently 
in response to a growing tumor. However, the innate immune mechanisms that promote 
natural antitumor T cell responses are undefined. In human metastatic melanoma, there 
was a correlation between a type I interferon (IFN) transcriptional profile and T cell mark-
ers in metastatic tumor tissue. In mice, IFN- was produced by CD11c+ cells after tumor 
implantation, and tumor-induced T cell priming was defective in mice lacking IFN-/R or 
Stat1. IFN signaling was required in the hematopoietic compartment at the level of host 
antigen-presenting cells, and selectively for intratumoral accumulation of CD8+ dendritic 
cells, which were demonstrated to be essential using Batf3/ mice. Thus, host type I IFNs are 
critical for the innate immune recognition of a growing tumor through signaling on CD8+ DCs.
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mediate sterile immunity against tumors arising from self tis-
sues. Reanalysis of the gene expression profiling data revealed 
that several transcripts indicative of type I IFN signaling, such 
as IRF1 and the IFN-induced protein of 30 kD were co-
expressed in those tumors that contained T cell transcripts (Fig. 1). 
This correlation prompted mechanistic experiments to deter-
mine whether host type I IFN signals might be necessary for 
spontaneous priming of CD8+ T cells against tumor antigens 
when it does occur.
We investigated whether spontaneous priming of anti-
gen-specific CD8+ T cells could be detected in lymphoid or-
gans  after  subcutaneous  implantation  of  murine  cell  lines   
in immunocompetent mice. To provide a defined antigen,   
tumor cells were transduced to express the model antigenic 
peptide SIYRYYGL (SIY) that is presented by the class I 
molecule Kb. The SIY antigen is advantageous because of the 
set of tools we have assembled for monitoring details of the 
host immune response, including peptide/MHC tetramers, 
TCR transgenic T cells, and high-affinity TCR tetramers to 
monitor  processed  antigen  on  APCs  (Kline  et  al.,  2008; 
Zhang et al., 2008). B16 melanoma cells expressing the SIY 
antigen (B16.SIY) induced a significant frequency of peptide- 
specific IFN-–producing cells in the spleen 6 d after sub-
cutaneous tumor implantation in the flank (Fig. 2 A). This was 
accompanied by an increase in the frequency of SIY-specific 
CD8+ T cells detected by SIY/Kb tetramer staining (Fig. 2 B). 
This T cell activation is completely dependent on cross-
presentation by host DCs, as it was ablated in CD11c-DTR 
transgenic mice treated with diphtheria toxin (Fig. S1). Flow 
cytometry confirmed that the majority of CD8+ and plas-
macytoid  DCs  (pDCs),  and  a  fraction  of  myeloid  DCs 
(mDCs), were depleted with this approach (Fig. S1). It is in-
teresting to note that these tumors grow progressively over 
time and are not ultimately rejected by the host, but this   
failure is not caused by an absence of early T cell priming. 
Rather, recent observations suggest that the immune response 
wanes over time because of dominant-negative regulatory 
mechanisms that eventually lead to tumor outgrowth (Kline 
et al., 2008). Regardless of those late events, early T cell 
from several groups have revealed that dying cells can release 
endogenous adjuvants (Kono and Rock, 2008), providing 
activation signals for DCs and other APCs that lead to up-
regulation  of  co-stimulatory  molecules  and  consequently 
yield productive T cell activation and differentiation (Kono 
and Rock, 2008). Although these early results indicate that 
tumor cells can, under certain conditions, liberate products 
that can theoretically elicit innate immune signals, how these 
or other signals may lead to the spontaneous activation of a 
tumor-specific adaptive T cell response remains unclear.
Type I IFNs have been studied extensively in the context 
of viral infections (Stetson and Medzhitov, 2006b). During 
various types of viral infection, type I IFNs induce the ex-
pression of an array of genes that act to prevent viral spread, 
thus creating an antiviral state (Stark et al., 1998). But type   
I IFNs also regulate antiviral immune effector responses and 
play an important role in promoting the cross-presentation of 
viral antigens to CD8+ T cells (Le Bon et al., 2003). Although   
a role for type I IFNs has been described for immunosurveil-
lance against carcinogen-induced tumors and for rejection   
of transplanted tumors (Dunn et al., 2005, 2006), the source 
of type I IFNs and the mechanism of action of this cytokine 
during the priming phase of an antitumor immune response 
have not yet been elucidated. We have recently reported   
that gene expression profiling of human melanoma metas-
tases revealed a subset of tumors that contained infiltrating 
CD8+ T cells (Harlin et al., 2009). Reasoning that interro-
gation of those gene array data might provide an indication 
regarding innate immune signals associated with the presence 
of a T cell response, we herein report a correlation between 
the presence of T cell–specific transcripts and a set of genes 
known to be induced by type I IFNs. Using a series of   
murine models, we show that shortly after tumor challenge   
in vivo, type I IFN production was detected by DCs in tumor- 
draining lymph nodes, and that host type I IFN signaling on 
CD8+ DCs was required for spontaneous cross-priming of 
tumor antigen–specific CD8+ T cells. Our results suggest a 
model in which a growing tumor can elicit production of 
type I IFNs from the host, which leads to accumulation of 
CD8+ DCs that in turn promote CD8+ T cell activation 
against tumor-derived antigens.
RESULTS
Tumors growing in immunocompetent hosts induce  
T cell priming and IFN- production by CD11c+ cells  
in tumor-draining lymph nodes
Gene expression profiling of human melanoma metastases 
along  with  confirmatory  assays  revealed  that  a  subset  of   
tumors showed evidence of spontaneous inflammation that 
included the presence of infiltrating CD8+ T cells (Harlin et al., 
2009). Parallel studies have indicated that among tumor- 
associated CD8+ T cells there are cells that recognize human 
melanoma antigens as reflected by class I MHC/peptide tet-
ramer staining (Speiser et al., 2002; Harlin et al., 2006). This 
evidence of spontaneous T cell priming against tumor anti-
gens raised the question of what innate immune signals might 
Figure 1.  Human melanoma metastases show a positive correla-
tion between T cell markers and IFN-induced transcripts. Tumor 
samples were obtained by core biopsy or excisional biopsy or obtained 
from material resected from patients as part of routine clinical manage-
ment. Total RNA was extracted from tumor samples (n = 52) and gene 
levels were analyzed by Affymetrix. Arbitrary expression units according 
to Affymetrix gene levels are shown. (IRF1, R2 = 0.648; p30, R2 = 0.658).JEM Vol. 208, No. 10 
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As an alternative approach to determining whether DCs were 
the  dominant  population  producing  IFN-,  we  depleted 
DCs  in  vivo  using  CD11c-DTR  transgenic  mice  treated 
with diphtheria toxin. After tumor implantation, these mice 
showed markedly reduced production of IFN- in the tumor-
draining lymph node compared with control mice (Fig. 2 E). 
Together, these results indicate that DCs are the major source 
of type I IFNs early after tumor challenge.
To determine whether this ability to induce a rapid host 
immune response and type I IFN production was a general 
phenomenon, an additional panel of C57BL/6-derived tumor 
cells was transduced to express the SIY antigen. All the tumor 
lines tested (EL4, MC57, and C1498) similarly induced a 
spontaneous CD8+ T cell response as assessed by ELISPOT 
(Fig. 2 F) and peptide/MHC tetramer analysis (not depicted), 
and IFN- production in the tumor-draining lymph node 
(Fig. 2 G). Together, these results indicated that it is not un-
common for implanted tumors to trigger type I IFN produc-
tion and a rapid CD8+ T cell response against tumor-associated 
antigens in vivo.
Host IFN-/ signaling is critical for spontaneous  
tumor-specific T cell priming
Having observed the early production of type I IFNs after 
tumor inoculation, we sought to determine whether host 
type I IFN signaling was necessary for spontaneous priming 
of CD8+ T cells to tumor antigens in vivo. We therefore ex-
amined the effect of B16.SIY challenge on the CD8+ T cell 
priming can be used in this model as a readout for determining 
the host innate immune requirements for the initial recogni-
tion of tumor.
To determine whether implanted tumors might also in-
duce a type I IFN profile in mice, we inoculated B16 mela-
noma cells into recombination-activating gene 2-deficient 
(Rag2/) mice, to eliminate a contribution of the adaptive 
immune system. We compared gene expression of the tumors 
recovered from the mice to the B16 cells grown in vitro, rea-
soning that the differentially expressed genes would be those 
induced in the host by the presence of the tumor. Interest-
ingly,  this  gene  expression  profiling  confirmed  the  up- 
regulation of multiple transcripts reflective of innate immune 
activation, including a panel of IFN-inducible genes (Table S1). 
A repeat of this experiment in type I IFNR/ mice con-
firmed that induction of these transcripts required type I IFN 
signaling on host cells (unpublished data). To assess directly 
whether type I IFNs are produced early in response to a 
growing  tumor,  we  compared  IFN-  mRNA  levels  by 
quantitative real-time PCR in lymph nodes from naive mice 
and from draining lymph nodes of C57BL/6 mice challenged 
with B16.SIY melanoma cells. We found that IFN- was 
produced in tumor draining lymph nodes as early as 4 d after 
tumor challenge (Fig. 2 C). We next sorted cells from tumor 
draining lymph nodes on the basis of their expression of the 
DC  marker  CD11c  and  analyzed  IFN-  mRNA  levels, 
which revealed that IFN- production after tumor challenge 
was confined to the CD11c+ DC subpopulation (Fig. 2 D). 
Figure 2.  Tumors induce CD8+ T cell 
priming, which is accompanied by IFN- 
production by CD11c+ DCs in the tumor-
draining lymph nodes. (A and B) C57BL/6 
mice were inoculated or not with 5 × 106 B16.
SIY tumor cells (s.c.), splenocytes were har-
vested 6 d later, and restimulated for 16 h in 
the presence or absence of soluble SIY peptide 
(A). The frequency of tumor-specific IFN-–
producing cells was assessed by ELISPOT.  
***, P < 0.0001 versus No tumor. (B) Cells were 
gated on CD8+CD4B220, and the frequency 
of SIY-specific CD8+ T cells was assessed by 
FACS using specific tetramers. **, P = 0.0063 
versus No tumor. (C and D) C57BL/6 mice 
were inoculated (s.c.) or not with 5 × 106 B16.
SIY tumor cells, and inguinal lymph nodes 
were recovered 4–6 d later. IFN- mRNA ex-
pression was assessed by real-time RT-PCR 
analysis in total lymph nodes, and the results are expressed as 2Ct using GAPDH as endogenous control. **, P = 0.0046 versus No tumor (C) or in CD11c+ 
and CD11c cells sorted from lymph nodes. ***, P = 0.0008 versus CD11c (D). (E) Wild-type C57BL/6 mice (expressing the congenic marker CD45.1+) were 
lethally irradiated and reconstituted with either wild-type (CD45.2+) or CD11c-DTR (CD45.2+) BM cells. Mice were allowed to reconstitute for 3 mo, and 
then were injected i.p. with diphtheria toxin (100 ng in 100 µl of DPBS) once a day for 8 d, starting 2 d before s.c challenge with 5 × 106 B16.SIY tumor 
cells in the left flank (n = 5). Inguinal lymph nodes were recovered 6 d later, and IFN- expression in total inguinal lymph nodes was measured by real-
time PCR. The results are expressed as 2Ct using 18s as endogenous control. (F and G) C57BL/6 mice were inoculated s.c. with the indicated tumor cell 
lines (5 × 106; F), and splenocytes were harvested 6 d later and restimulated for 16 h in the presence or absence of soluble SIY peptide. Frequency of  
tumor-specific IFN-–producing cells was assessed by ELISPOT. (G) Real-time RT-PCR analysis of IFN- mRNA expression in total inguinal lymph nodes. 
The results are expressed as 2Ct using 18s as endogenous control. Data represent mean ± SEM (n = 5) and are representative of four independent ex-
periments (A–C) or two independent experiments (D–G).2008 Type I IFNs and CD8+ DCs in antitumor immunity | Fuertes et al.
reconstituted with wild-type BM cells rejected the tumor 
normally, indicating that the expression of Stat1 in hemato-
poietic cells is sufficient for tumor rejection and that Stat1 
expression is not required in non-BM-derived cells for tumor 
response to the SIY tumor antigen in mice deficient for the 
IFN-/R compared with WT mice. 17 d after tumor in-
oculation,  splenocytes  were  assayed  for  the  frequency  of 
IFN-–producing cells in response to soluble SIY peptide or 
irradiated B16.SIY cells by ELISPOT. In comparison to the 
vigorous response observed in the wild-type group, spleno-
cytes from IFN-/R/ mice displayed a dramatically re-
duced  frequency  of  IFN-–producing  effector  cells  after 
tumor challenge (Fig. 3 A). To determine whether the effect of 
type I IFNs on T cell priming was at the level of expansion 
versus differentiation of CD8+ T cells, analysis using SIY/Kb 
tetramers was performed. Whereas an expanded population of 
tetramer-reactive CD8+ T cells was detected in the spleens of 
wild-type mice, IFN-/R/, and IFN-/R//IFN-R/  
mice  failed  to  display  an  increased  frequency  of  tumor   
reactive CD8+ T cells (Fig. 3 B). The combined elimina-
tion  of IFN-/R and IFN-R reduced T cell priming 
completely to background levels, suggesting partial compen-
sation by IFN- in the absence of type I IFN signaling. 
However, mice singly deficient in the IFN-R generated a 
normal expanded frequency of SIY-specific CD8+ T cells 
(Fig. 3 C), suggesting that type I IFNs are dominantly re-
quired and that IFN- is not necessary for this stage of an   
antitumor T cell response.
As type I IFNs mediate signaling through Stat1, we 
additionally analyzed spontaneous CD8+ T cell priming in 
Stat1/ mice. Consistent with our previous results, Stat1/ 
mice also showed a markedly decreased priming of tumor 
antigen–specific CD8+ T cells as assessed by ELISPOT and 
SIY/Kb tetramer analysis (Fig. 3, D and E). Together, these 
results indicate that host type I IFN signaling through Stat1 is 
required  for  optimal  expansion  of  tumor  antigen–specific 
CD8+ T cells after tumor challenge in vivo.
IFN signaling is required in the hematopoietic compartment 
for spontaneous rejection of tumors in vivo
To determine whether the defect in natural CD8+ T cell prim-
ing in the absence of host IFN signaling would be associated 
with failed tumor rejection, we used a model in which tumors 
are spontaneously rejected. At the same time, it was of interest 
to determine the cellular compartment in which IFN signaling 
must occur. Toward this end, we turned to the immunogenic 
variant of the P815 mastocytoma, P198, which initially grows 
but  is  spontaneously  rejected  in  syngeneic  DBA/2  mice   
(Fallarino et al., 1996). To determine if type I IFN signaling for   
tumor rejection was required in the hematopoietic or nonhe-
matopoietic compartment, we generated radiation BM chime-
ras in which Stat1-sufficient versus Stat1/ DBA/2 mice were 
irradiated and reconstituted with either wild-type or Stat1/ 
DBA/2 BM cells. After a period of at least 3 mo, to allow for 
recovery of the immune system, mice received a tumor chal-
lenge with P198 cells on the flank and were monitored for   
tumor progression. As expected, P198 cells were rejected by 
wild-type mice that had been reconstituted with wild-type 
BM, and tumors grew progressively in Stat1/ mice reconsti-
tuted with Stat1/ BM (Fig. 4 A). In contrast, Stat1/ mice 
Figure 3.  IFN-/, and not IFN- signaling, is critical for sponta-
neous CD8+ T cell priming to tumor-associated antigens.  
(A and B) Wild-type, IFN-/R/, or IFN-/R//IFN-R/ mice were 
inoculated s.c. with 106 B16.SIY tumor cells. Splenocytes were harvested 
17 d later and restimulated for 16 h in the presence or absence of or sol-
uble SIY peptide (A). The frequency of tumor-specific IFN-–producing 
cells was assessed by ELISPOT. ***, P < 0.0001 versus WT. (B) cells were 
gated on CD8+CD4B220 and the frequency of SIY-specific CD8+ T cells 
was assessed by FACS using specific tetramers. ***, P < 0.0009; **, P < 
0.0027 versus WT. (C) Wild-type and IFN-R/ mice were inoculated s.c. 
with 106 B16.SIY tumor cells, and splenocytes were harvested 17 d later 
and restimulated for 16 h in the presence or absence of soluble SIY pep-
tide, and then the frequency of tumor-specific IFN-–producing cells was 
assessed by ELISPOT. P = 0.268 versus WT. (D and E) Wild-type and 
Stat1/ mice were inoculated s.c. with 106 B16.SIY tumor cells, and  
splenocytes were harvested 17 d later and restimulated for 16 h in the 
presence or absence of soluble SIY peptide (D). The frequency of tumor- 
specific IFN-–producing cells was assessed by ELISPOT. ***, P < 0.0001 
versus WT. (E) cells were gated on CD8+CD4B220, and the frequency  
of SIY-specific CD8+ T cells was assessed by FACS using specific tetramers. 
**, P = 0.0029 versus WT. Data represent mean ± SEM (n = 5), and are 
representative of three independent experiments.JEM Vol. 208, No. 10 
Article
2009
compartment is necessary for spontaneous tumor rejection 
in vivo and that Stat1 in non-BM-derived cells is not sufficient 
for tumor rejection (Fig. 4 A).
IFN signaling is required in non-T cell BM-derived cells  
for tumor antigen–specific T cell priming
Among the cells of the hematopoietic compartment, IFN 
signaling could be playing a T cell–intrinsic role in the gen-
eration of an antitumor immune response and/or be impor-
tant in non–T cells, perhaps at the level of APCs. To address 
whether T cell–intrinsic IFN signaling was required for the 
acquisition of an effector phenotype, we compared wild-type 
and Stat1/ T cells primed to become effector CTL in a 
mixed lymphocyte culture in vitro. However, Stat1/ and 
wild-type T cells were equally able to lyse allogeneic target 
cells (Fig. 4 B), suggesting that T cell–intrinsic Stat1 is not 
absolutely required for the development and execution of 
lytic effector function by cytotoxic T lymphocytes. IFN- 
production by Stat1/ CTL was also preserved (unpublished 
data). To investigate more directly whether IFN signaling on 
non–T cells was required for activation of tumor antigen–
specific CD8+ T cells, we CFSE labeled wild-type CD8+  
T cells purified from 2C TCR Tg/Rag2/ mice (Sha et al., 
1988) specific for the SIY octameric peptide in the context of 
Kb (Udaka et al., 1996) and adoptively transferred them into 
wild-type or Stat1/ syngeneic mice. We then challenged 
the mice with B16.SIY tumors. 7 d after tumor challenge 
with B16.SIY, we analyzed CFSE dilution of SIY-specific 
CD8+ T cells in the spleen. A large percentage of the 2C 
CD8+ T cells transferred into wild-type mice displayed a   
decreased  intensity  of  CFSE  fluorescence,  consistent  with   
antigen-specific  T  cell  proliferation  and  successful  cross- 
presentation of the SIY antigen. In contrast, CFSE dilution was 
markedly reduced upon transfer into Stat1/ hosts (Fig. 4,   
C and D). Finally, to determine whether T cell priming could 
occur in the absence of T cell–intrinsic IFN signaling in vivo, 
we vaccinated Stat1/ versus wild-type mice with wild-type 
BM-derived DCs (BMDCs) loaded with SIY peptide. When 
assayed 20 d later for T cell priming by IFN- ELISPOT, 
comparable induction of SIY-specific T cells was observed in 
both wild-type and Stat1/ hosts (Fig. 4 E). This result demon-
strates that T cell–intrinsic IFN signaling is not required for 
T cell priming in vivo, and suggests that the defect in T cell 
priming lies upstream, likely at the level of host APCs.
Analysis of DC subsets from mice deficient in IFN signaling
In  a  search  for  potential  mechanisms  responsible  for  the 
lack of tumor antigen–specific CD8+ T cell priming in the   
absence of host IFN signaling, we analyzed multiple pheno-
typic characteristics of DCs from wild-type versus Stat1/  
or IFN-/R/ mice. We first compared frequencies and   
absolute numbers of the different DC subpopulations (mDCs,   
CD11C+B220CD8CD11b+;  CD8+DCs,  CD11C+ 
B220CD8+CD11b; and pDCs, CD11CintB220+PDCA+) 
in the spleen and lymph nodes of unmanipulated or tumor- 
bearing mice but found no difference between Stat1/ or 
Figure 4.  IFN signaling is required in non–T cell BMDCs for tumor-
specific T cell priming and for spontaneous rejection of immunogenic 
tumors in vivo. (A) Wild-type and Stat1/ DBA/2 mice were lethally  
irradiated and reconstituted with either wild-type or Stat1/ DBA/2 BM 
cells, and 3 mo later they were challenged s.c. with 106 P198 cells in the left 
flank (n = 5). Tumor size was measured at different time points. Results are 
shown as mean tumor diameter ± SEM. Data are representative of two 
independent experiments. (B) T cells from wild-type and Stat1/ (H-2b) 
mice were stimulated with T cell–depleted irradiated splenocytes from 
DBA/2 (H-2d) mice for 5 d in an allogeneic MLR. Cytotoxic activity was mea-
sured by standard 51Cr-release assay against P815 (H-2d, cognate targets) 
and EL4 cells (H-2b, control targets). (C and D) CD8+ T cells were purified 
from the spleens of 2C Tg/RAG2/ (Stat1-sufficient) mice, CFSE labeled, 
and transferred by retroorbital injection to wild-type or Stat1/ mice. The 
next day, those mice were inoculated s.c. with 106 B16.SIY cells in the flank, 
and 7 d later splenocytes were harvested and CFSE dilution of 2C CD8+  
T cells was assessed by FACS. (C) Percent of cells with decreased CFSE inten-
sity within the DAPICD8+1B2+ gate. Data show mean ± SEM of individual 
mice in each group. Data are representative of two independent experi-
ments. (D) Representative dot plots of CFSE dilution. Numbers indicate per-
cent of cells in the indicated gate. (E) 106 SIY-pulsed wild-type BMDCs were 
s.c. inoculated in the flank of wild-type or Stat1/ mice, and 20 d later 
splenocytes were harvested and restimulated in vitro for 16 h in the pres-
ence of culture medium or soluble SIY peptide. The frequency of tumor-
specific IFN-–producing cells was assessed by ELISPOT. Data are 
representative of two independent experiments.
immunity (Fig. 4 A). In addition, the failure of wild-type mice 
reconstituted  with  Stat1/  BM  to  reject  the  P198  tumor 
demonstrates that expression of Stat1 in the hematopoietic 2010 Type I IFNs and CD8+ DCs in antitumor immunity | Fuertes et al.
IFNs would induce chemokines by the DCs that would aid 
in the recruitment of T cells to the lymph node for subse-
quent activation. Analysis of DCs stimulated with IFN/ 
revealed substantial production of CXCL9 and CXCL10, 
which  could  potentially  mediate  recruitment  of  activated 
CD8+  T  cells  via  CXCR3  (unpublished  data).  However, 
there was no defect in priming of SIY-specific CD8+ T cells 
in response to B16.SIY tumors in CXCR3/ mice (unpub-
lished data), arguing for a lack of importance of this pathway 
at the early stages of T cell priming in vivo. Finally, it was 
reasoned that type I IFN signaling might be necessary for 
DCs to be able to take up, process, and present tumor antigen 
in the context of class I MHC molecules. This possibility was 
addressed  through  the  use  of  tetramers  generated  from  a 
high-affinity variant of the 2C TCR, which can bind to   
SIY–Kb complexes with sufficient avidity to allow analysis   
by flow cytometry. Analysis of the APC compartments was 
performed in wild-type versus Stat1/ mice crossed to a 
RAG2/ background, to eliminate the possibility that host 
T cells might eliminate antigen-expressing APCs. In fact, 
when tumor-derived CD11c+ or CD11b+ cells were ana-
lyzed from wild-type versus Stat1/ RAG2/ mice bear-
ing MC57.SIY tumors, comparable binding of the 2C TCR 
tetramer was observed (Fig. 5, C and D). Absence of binding 
to APCs derived from wild-type MC57 tumors confirmed 
specificity of tetramer binding only when the SIY antigen 
was present. These results suggest that the APC subsets that 
accumulate in the tumor site process and present the SIY   
tumor-derived antigen normally, even in the absence of host 
type I IFN signaling.
In vivo, endogenous type I IFN signaling is required  
for intratumoral accumulation of the CD8+ DC subset
Given the comparable properties of DC subsets in the lym-
phoid organs of wild-type and Stat1/ mice, and the intact 
expression of SIY–Kb peptide–MHC complexes on the total 
APC populations that are present within the tumor site, we 
next addressed whether there was a defect at the level of   
the specific DC subsets that accumulate within the tumor 
microenvironment.  We  therefore  challenged  wild-type 
and Stat1/ mice with B16.SIY cells and evaluated the fre-
quency and absolute number of the three major DC subpop-
ulations accumulating in the tumor at day 16. We found 
that the mDC and pDC subpopulations accumulated in the   
tumors of both groups of mice. However, the CD8+ DC 
population, which accounted for up to 20% of the DCs infil-
trating the tumors in wild-type mice, was almost completely 
absent in the tumors grown in Stat1/ mice (Fig. 6, A and B; 
and Fig. S2). A similar defect in CD8+ DC accumulation 
was observed in IFN-/R/ mice (Fig. 6 C). As an alter-
native  quantitative  approach  to  evaluate  the  presence  of 
CD8+ DCs, molecular markers were used. XCR1 is a   
chemokine receptor exclusively expressed by CD8+ DCs 
(Dorner et al., 2009) and Batf 3, a transcription factor prefer-
entially expressed by CD8+ DCs and absolutely required for 
their development. Using quantitative RT-PCR to analyze 
IFN-/R/ and wild-type mice (unpublished data). In 
addition, the surface expression of CD80, CD86, CD40, and 
class I and class II MHCs in CD11c+ tumor-draining lymph 
node  cells  was  comparable  (Fig.  5  A  and Table  S2),  and 
LPS-induced IL-12 production was still detected in Stat1/ 
CD11c+ cells (not depicted). Moreover, adherent splenocytes 
from wild-type and Stat1/ mice did not differ in their abil-
ity to stimulate 2C TCR Tg CD8+ T cells to produce IL-2 
upon loading with the SIY peptide in vitro (Fig. 5 B).
It was conceivable that host IFN signaling was generally 
important for the migration of DCs into the draining lymph 
node compartment in vivo. To address this possibility, the 
skin of wild-type and Stat1/ mice was painted with FITC 
and the draining lymph nodes were analyzed for green fluo-
rescence on CD11c+ cells. However, comparable appearance 
of FITC+ DCs was observed in both sets of mice (unpub-
lished data). We also considered the possibility that type I 
Figure 5.  Analysis of DCs from WT, Stat1/, and IFN-/R/ 
mice. (A) Wild-type and IFN-/R/ mice were inoculated s.c. with 106 
B16.SIY cells. 6 d later, surface expression of CD80, CD86, CD40, and class I 
and II MHC was assessed by FACS in tumor-draining lymph node cells 
gated on CD11c+ cells. Filled histograms correspond to an isotype control (IC), 
continuous line corresponds to wild-type, and dashed line corresponds  
to IFN-/R/ mice. (B) Adherent splenocytes from wild-type and 
Stat1/ mice were loaded with SIY peptide or left untreated and used  
to stimulate 2C CD8+ T cells. IL-2 production was assessed by ELISA.  
(C and D) Wild-type Rag1/ mice (top) or Rag1/Stat1/ mice (bottom) 
were inoculated with 106 MC57 or MC57.SIY tumor cells. 14 d later SIY/Kb 
expression was assessed by FACS using high-affinity 2C TCR tetramers 
gated on the tumor-infiltrating CD11c+ population (C) and CD11b+ popu-
lation (D). Filled histograms correspond to staining with streptavidin-
phycoerythrin alone. Data are representative of two independent 
experiments (n = 4).JEM Vol. 208, No. 10 
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in Batf3/ and IFN-/R/ mice (Fig. S3, A and B). More-
over, parental B16 melanoma cells, without the SIY antigen, 
also grew faster in Batf3/ mice compared with wild-type   
(Fig. S3 C), indicating that this is a critical pathway for cross-
presentation of natural endogenous tumor antigens. To deter-
mine whether CD8+ DCs were themselves required for type I 
IFN production in response to tumor implantation, induction of 
IFN- mRNA was assessed in tumor-draining lymph nodes in 
wild-type versus Batf3/ mice. However, IFN- induction 
was comparable in both sets of mice (Fig. 7 C). Collectively, 
these findings demonstrate that the CD8+ DC subpopulation 
is critical for the spontaneous priming of tumor antigen–specific 
CD8+ T cells in response to a growing tumor, downstream from 
host type IFN production.
To  determine  whether  the  CD8+  DC  lineage  itself   
must respond to type I IFNs, wild-type mice were irradiated 
and reconstituted with wild-type, Batf3/ or IFN-/R/ 
BM cells, or a mix of wild-type and IFN-/R/ or 
Batf3/ and IFN-/R/ in a 50/50 ratio. 3 mo later, those 
chimeric mice were challenged with B16.SIY melanoma cells,   
and splenocytes were assayed 6 d later for T cell priming by 
SIY/Kb tetramer analysis and tumor size was measured. As   
expected, mice reconstituted with Batf3/ or IFN-/R/ 
BM cells showed a dramatically reduced frequency of SIY-
specific CD8+ T cells as compared with mice reconstituted 
with wild-type BM cells (Fig. 8 A). Mice reconstituted with a 
mix of wild-type and IFN-/R/ cells showed restored   
T cell priming to the level seen in wild-type mice. However, 
mice reconstituted with a mix of Batf3/ and IFN-/R/ 
BM cells continued to show reduced priming of SIY-specific 
T cells (Fig. 8 A). This reduced T cell priming was associated 
with poor tumor growth control (Fig. 8 B). These results dem-
onstrate that type I IFNs must signal on the CD8+ DC   
lineage for optimal priming of tumor antigen–specific CD8+  
T cells after tumor challenge in vivo.
transcript abundance in tumors analyzed ex vivo, we found 
that both transcripts were highly expressed in tumors grown 
in wild-type mice, yet severely reduced in tumors grown in 
IFN-/R/ mice (Fig. 6, D and E). Therefore, host IFN 
signaling appeared to be required for intratumoral accumula-
tion of CD8+ DCs within the tumor microenvironment.
CD8+ DCs have been shown to be the most important 
DC  population  for  cross-presentation  of  antigens  to  CD8+  
T cells in the setting of viral infection (Belz et al., 2004). Recent 
work has indicated that mice lacking the transcriptional regula-
tor, Batf3, have a specific deficiency in the development of the 
CD8+ DC lineage (which includes a CD103+ DC subset; 
Hildner et al., 2008). These mice also show defective cross-
priming of CD8+ T cells in response to viruses, and were defec-
tive in control of immunogenic tumors in vivo (Hildner et al., 
2008). We therefore investigated whether these DC subpopula-
tions were required at the level of priming of CD8+ T cells to 
tumor-derived antigens. Wild-type and Batf3/ mice were 
challenged with B16.SIY melanoma cells, and splenocytes were 
assayed 6 d later for the frequency of IFN-–producing cells 
by  IFN- ELISPOT and SIY/Kb tetramer staining. Indeed, 
Batf3/  mice  showed  a  dramatically  reduced  frequency  of 
IFN-–producing  effector  cells  as  compared  with  wild-type 
mice (Fig. 7, A and B). The poor T cell priming was comparable 
to  the  level  of  deficiency  observed  in  IFN-/R/  mice   
(Fig. 3 A), as was the tumor growth rate, which was accelerated 
Figure 6.  Endogenous type I IFN signaling is required for intra-
tumoral accumulation of CD8+ DCs. (A and B) Wild-type and Stat1/ 
mice were inoculated s.c. with 106 B16.SIY cells, and 15 d later tumors 
were harvested and frequency (A) and percentages (B) of CD8+ DCs, 
mDCs, and pDCs infiltrating tumors were analyzed by FACS. 
GFP+DAPI+CD3+ cells were gated out, and the different DCs subpopula-
tions were identified as follows: mDCs, CD11C+B220CD8CD11b+; 
CD8+DCs, CD11C+B220CD8+CD11b; and pDCs, CD11CintB220+PDCA+. 
Results are shown as mean ± SEM of 3 independent experiments (n = 4). 
(C–E) Wild-type and IFN-/R/ mice were inoculated s.c. with 106 B16.
SIY cells, and 15 d later tumors were harvested and frequency of intra-
tumoral CD8+ DCs was assessed by FACS (C). (D and E) XCR1 mRNA ex-
pression (D) and Batf3 mRNA expression (E) were assessed by real-time 
RT-PCR analysis on tumor homogenates. The results are expressed as 
2Ct using 18s as endogenous control. Results are shown as mean ± 
SEM of 2 independent experiments (n = 5).
Figure 7.  CD8+ DCs are critical for antitumor CD8+ T cell prim-
ing. Wild-type and Batf3/ mice were inoculated s.c. with 106 B16.SIY 
cells. 6 d later, splenocytes were harvested and restimulated for 16 h in 
the presence of culture medium or soluble SIY peptide (A). The frequency 
of tumor-specific IFN-–producing cells was assessed by ELISPOT. ***, P < 
0.0001 versus WT. (B) the frequency of SIY-specific CD8+ T cells was  
assessed by FACS using specific anti–Kb-SIY tetramers, cells were gated on 
the CD8+CD4B220 population. ***, P < 0.001 versus WT. (C) IFN- 
mRNA expression was assessed by real-time RT-PCR analysis in total 
lymph nodes. The results are expressed as 2Ct using 18s as endogenous 
control. Results are shown as mean ± SEM (n = 5) and are representative 
of at least two experiments.2012 Type I IFNs and CD8+ DCs in antitumor immunity | Fuertes et al.
pathway leading to IRF3 activation and to type I IFN pro-
duction (Stetson and Medzhitov, 2006a). It is interesting to 
speculate that a TLR-independent cytosolic DNA recogni-
tion pathway might be involved in innate tumor recognition, 
IFN- production, and spontaneous priming of tumor antigen– 
specific T cells.
Our  data  have  demonstrated  that,  shortly  after  tumor 
challenge, IFN- is produced by CD11c+ DCs in tumor-
draining lymph nodes. However, the identity of the specific 
subset of DCs producing type I IFNs in response to tumor 
growth remains unclear. The fact that IFN- production is 
still  observed  in  Batf3/  mice  strongly  suggest  that  the 
CD8+ DC subpopulation is not required for type I IFN 
production. Preliminary studies of depletion of pDCs using 
the anti-PDCA (Krug et al., 2004) mAb have revealed that   
T cell priming and IFN- production appear to be intact 
(unpublished  data).  Thus,  it  may  be  that  conventional 
mDCs are capable of this function. Nonetheless, our data 
are consistent with a model in which at least two different 
DC subpopulations collaborate for the induction of sponta-
neous antitumor T cell priming. In this model, one DC sub-
population (likely either mDCs or pDCs) would sense the 
presence  of  the  tumor  and  produce  type  I  IFNs,  which 
through signaling on CD8+ DCs would promote effective 
cross-priming of CD8+ T cells. Consistent with this model, it 
has been recently shown using quantitative proteomics that   
the CD8+ DC subpopulation selectively lacks the receptors 
and signaling molecules (such as DAI [Takaoka et al., 2007]   
and Sting [Ishikawa et al., 2009]) required for the detection of   
nucleotides in the cytoplasm (Luber et al., 2010), so if this is in-
deed the pathway involved in type I IFN production to tumor, 
a non-CD8+ DC subpopulation would need to be involved.
Although several studies have suggested that CD8+ DC 
distribution is restricted to lymphoid organs (Randolph et al., 
2008) our results clearly indicate that CD8+ DCs (defined   
as CD3CD11c+B220CD11bCD8+ cells) can infiltrate   
tumors. In agreement with our findings, it has been reported 
that CD8+ DCs can infiltrate transplantable and spontane-
ous melanomas in B6 mice (Preynat-Seauve et al., 2006) and 
sarcomas in BALB/c mice treated with Flt3L and GM-CSF 
(Berhanu et al., 2006), and that such recruitment is associated 
with tumor rejection. Even though we found an augmented 
expression of XCR1 transcripts in tumors growing in wild-
type  hosts  compared  with  type  I  IFN  receptor–deficient 
mice, this difference could not be explained by a differential 
expression of its ligand, the chemokine XCL1, which was 
present in the tumor microenvironment in both hosts (un-
published data). The detailed mechanism by which type I 
IFNs induce the intratumoral accumulation of CD8+ DCs 
will be a crucial area for future investigation.
It is noteworthy that, under conditions in which sponta-
neous priming of antitumor CD8+ T cells was not occurring, 
we detected expression of processed SIY peptide–Kb com-
plexes on the surface of several subsets of APCs. These results 
suggest that APC subtypes other than CD8+ DCs are   
capable of processing antigen into the class I compartment. 
DISCUSSION
Our results identify type I IFNs as critical mediators in the 
spontaneous priming of an antitumor CD8+ T cell response. 
Our data show that IFN- is produced shortly after tumor 
challenge and, through signaling at the level of CD8+ DCs, 
promotes tumor antigen–specific T cell priming and tumor 
rejection. In vivo, endogenous type I IFNs induced the intra-
tumoral accumulation of CD8+ DCs, which were essential 
for spontaneous antitumor CD8+ T cell priming and which 
could explain the critical role of this cell lineage in spontane-
ous cross-priming of tumor antigen–specific CD8+ T cells.
Given the lack of external TLR ligands for most malig-
nancies, the molecular mechanism by which a tumor can 
provide the right environment to stimulate immune activa-
tion remains poorly understood. Emerging evidence indicates 
that dying cells can release endogenous adjuvants capable of 
activating APCs (Kono and Rock, 2008). Among these mol-
ecules are heat-shock proteins (Basu et al., 2000), uric acid 
(Shi  et  al.,  2003),  HMGB1  (high-mobility-group  box  1; 
Scaffidi et al., 2002), ATP (Haag et al., 2007), and genomic 
double-stranded (ds) DNA (Ishii et al., 2001). It has been re-
cently demonstrated that after radiotherapy or chemotherapy, 
dying tumor cells can release HMGB1 that binds to TLR4 
(Apetoh et al., 2007) and ATP that activates the NALP3 in-
flammasome (Ghiringhelli et al., 2009). Presumably there is 
some degree of spontaneous tumor cell death either upon 
implantation of transplantable tumor cell lines or, as tumor 
growth exceeds the available blood supply during attempted 
neoangiogenesis. However, the massive tumor cell death   
occurring with chemotherapy or radiation is unlikely to be 
present in our system of spontaneous T cell priming, so other 
mechanisms could be operational. Recently, it has been shown 
that dsDNA can be released from necrotic cells, reach the 
cytoplasm of APCs, and be recognized by a TLR-independent 
Figure 8.  Type I IFN signaling must occur on the CD8+ DC lineage  
for antitumor CD8+ T cell priming to occur. (A) Wild-type mice were 
lethally irradiated and reconstituted with wild-type, Batf3/, or IFN-
/R/ BM cells, or a mix of wild-type and IFN-/R/ or Batf3/ 
and IFN-/R/ in a 50/50 proportion. Mice were allowed to reconsti-
tute for 3 mo, and were then inoculated s.c. with 106 B16.SIY cells.  
(A) splenocytes were harvested 6 d later, and the frequency of SIY-specific 
CD8+ T cells was assessed by FACS using specific tetramers. Cells were 
gated on CD8+CD4B220. (B) Tumor size was measured at the end of 
the experiment. *, P < 0.05 versus IFN-/R/ + WT. Results are shown 
as mean ± SEM of 2 independent experiments (n = 4 each).JEM Vol. 208, No. 10 
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of type I IFNs, which are already FDA approved for other 
indications, in order to promote improved activation of   
tumor antigen–specific CD8+ T cells using the tumor itself as 
a source of antigen.
MATERIALS AND METHODS
Human samples and gene array analysis. Biopsy processing and gene 
array analysis were described previously (Harlin et al., 2009). Data were   
interrogated for expression of IFN-regulated genes and referenced to TCR 
transcripts in individual tumors.
Mice. C57BL/6 mice, 129 mice, and Stat1/ mice were purchased from 
Taconic. For the indicated experiments, Stat1/ mice were backcrossed for 
six generations onto DBA/2 mice (Jackson ImmunoResearch Laboratories). 
IFN-R/  mice  were  obtained  from  The  Jackson  Laboratory.  IFN-
R/ mice and IFN-/R/IFN-R/ mice were purchased from 
B&K Universal. Batf3/ mice (Hildner et al., 2008) were obtained from   
K. Murphy (Washington University School of Medicine, St. Louis, MO). 
Experiments in these strains were done either on the 129 or the C57BL/6 
background (at least 5 generations) with similar results. 2C/RAG2/ mice 
(Sha  et  al.,  1988)  were  obtained  from  D.  Loh  (Washington  University 
School of Medicine, St. Louis, MO). CD11c-DTR mice (Jung et al., 2002) 
were provided by D. Littman (New York University School of Medicine, 
New York, NY). All mice were used between 6 and 10 wk of age and were 
maintained in specific pathogen–free conditions in a barrier facility at the 
University of Chicago (Chicago, Illinois). All animal experiments were per-
formed in accordance with protocol approved by the University of Chicago 
Institutional Animal Care and Use Committee.
Tumor cell lines. The mutagenized DBA/2-derived mastocytoma cell line 
P198 and the C57BL/6 derived melanoma cell lines B16.F10 and B16.F10.
SIY (henceforth referred to as B16.SIY), thymoma cell lines EL4 and EL4.
SIY, fibrosarcoma cell lines MC-57 and MC-57.SIY, and the leukemia cell 
line C1498.SIY were used for experiments. All cells were maintained at 
37°C with 7.5% CO2 in DME supplemented with 10% heat-inactivated 
FCS, MOPS, 2-mercaptoethanol, penicillin, streptomycin, l-arginine,   
l-glutamine, folic acid, and l-asparagine.
In vivo tumor experiments. Cultured tumor cells were washed three 
times with Dulbecco’s PBS (DPBS), and 106 living cells were injected s.c. in 
100 µl DPBS on the flank. For tumor growth experiments, the longest and 
shortest diameters were measured twice per week using calipers, and a mean 
and SD were calculated. For ELISPOT, tetramer staining, and CFSE dilu-
tion splenocytes were analyzed at the indicated time points after tumor chal-
lenge.  For  RT-PCR  analysis  of  IFN-,  tumor-draining  inguinal  lymph 
nodes were collected and analyzed 4 to 6 d after tumor challenge. For analy-
sis of tumor-infiltrating DC subpopulations, tumors were recovered 15 d   
after tumor challenge and were disrupted in complete DME medium con-
taining 1 mg/ml collagenase IV (Sigma-Aldrich) for 30 min at 37°C. Data 
from groups of three to seven mice were analyzed.
IFN- ELISPOT. The enzyme-linked Immunospot assay (ELISPOT) was 
conducted with the BD mouse IFN- kit according to the manufacturer’s 
protocol. Splenocytes were plated at 106 cells/well and stimulated overnight 
with  irradiated  (10,000  rad)  B16.SIY  cells  (5  ×  104/well),  SIY  peptide   
(80 nM), or PMA (50 ng/ml) and ionomycin (0.5 µM). In experiments ana-
lyzing priming by BMDCs, the restimulation was performed in FCS-free 
culture medium and plates were not blocked. IFN- spots were detected   
using biotinylated antibody and avidin-peroxidase and developed using AEC 
substrate (Sigma-Aldrich). Plates were read in an Immunospot Series 3 Ana-
lyzer and analyzed with ImmunoSpot software (Cellular Technology Ltd).
Flow cytometry. Cells were incubated for 15 min at 4°C with anti-CD16 
monoclonal antibody (2.4G2) to block potential nonspecific binding and 
Similar results have been reported by others. Hans Schreiber’s 
laboratory has observed expression of processed tumor- 
derived  antigen  in  tumor-infiltrating  macrophages  (Zhang   
et al., 2007). In addition, in the TRAMP model, tumor- 
infiltrating DCs have been suggested to express processed   
antigen and behave in a tolerogenic rather than an activating 
fashion (Anderson et al., 2007). Thus, although the CD8+ 
DC subset is quantitatively superior at cross-presenting exog-
enous antigen into the class I compartment, it is likely that 
additional qualitative differences explain their ability to better 
initiate CD8+ T cell priming. Although it would have been 
ideal to characterize the DCs that had successfully processed 
antigen  and  then  trafficked  to  the  tumor-draining  lymph 
node, we were unable to detect such cells with the TCR tet-
ramer in the lymph node compartment, arguing that the pre-
sumably  small  number  of  cells  is  below  the  threshold  of 
detection. It also should be pointed out that we studied DC 
subsets in the tumor microenvironment at relatively late time 
points, because in small tumors it simply wasn’t technically 
possible to detect them reliably. So we can only infer that a 
similar defect in CD8+ DC accumulation is occurring at 
early times after tumor implantation. Nonetheless, our subse-
quent experiments solidified a requirement for CD8+ DCs, 
and for type I IFN signaling on these cells, in order to attain 
spontaneous CD8+ T cell priming.
It  is  currently  unknown  what  dictates  why  tumors  in 
some patients are capable of inducing spontaneous tumor-
antigen specific T cell priming whereas others are not. Single 
nucleotide polymorphisms (SNPs) in different genes involved 
in the type I IFN pathway have been reported, including   
IFNAR (Muldoon et al., 2001) and Stat1 (Fortunato et al., 
2008), that could affect levels of expression of the mature 
proteins, leading to variation in the response to type I IFNs. 
Alternatively, activation of distinct combinations of onco-
genic pathways in individual tumors could lead to expression 
of distinct sets of genes that facilitate innate immune recogni-
tion in vivo.
The involvement of type I IFNs in antitumor immune 
responses has been appreciated for a number of years. Al-
though early clinical trials of systemic administration of type I 
IFNs showed encouraging results for the treatment of a 
broad range of tumors (Neidhart et al., 1984; Motzer et al., 
2002), the mechanism by which exogenously administered 
type I IFNs induces antitumor activity has remained elusive. 
In  addition,  injection  of  mice  with  blocking  antibody  to 
IFN-/ has been reported to enhance tumor growth, sug-
gesting the importance of endogenous type I IFNs after   
tumor challenge and a role in inhibiting tumor growth in 
immunocompetent mice (Gresser et al., 1983). Our findings 
now describe a link between spontaneous IFN- production 
and signaling on CD8+ DC which is essential for tumor   
antigen–specific CD8+ T cell priming. In addition, preliminary 
data have revealed potent rejection of B16 melanoma when 
transduced to express IFN- (unpublished data). Collectively, 
our results have implications for human cancer therapy, pro-
viding a strong rationale for the intratumoral administration 2014 Type I IFNs and CD8+ DCs in antitumor immunity | Fuertes et al.
BMDC immunization. BMDCs were generated according to a modified 
version of a published protocol (Inaba et al., 1992). BM cells from the tibiae 
and femora were ACK-lysed and incubated for 10 d in complete DME me-
dium with 20 ng/ml rmGM-CSF (R&D Systems) with the addition of   
200 ng/ml LPS (Sigma-Aldrich) for the last 24 h. On day 10, cells were ex-
posed to 10 µM SIY peptide for 1 h at 37°C and washed 3 times with DPBS. 
Mice were injected s.c. in the flank with 106 BMDCs in 100 µl DPBS.
Adherent splenocyte stimulation of CD8+ T cells. Splenocytes were 
ACK-lysed, irradiated (5,000 rad), and plated at 106 cells/well. After 2 h of 
incubation, nonadherent cells were removed by 2 washes with DPBS. To 
stimulate CD8+ T cells, SIY peptide (10 µM) or culture medium was added 
to the adherent splenocytes, followed by the addition of 5 × 104 naive 2C/
RAG2/ CD8+ T cells/well. Supernatants were collected after 18 h and 
IL-2 production was determined by ELISA.
Statistical methods. Differences between datasets were analyzed with the 
two-sided Student’s t test, and correlation was analyzed with Pearson test and 
Prism software (GraphPad).
Online supplemental material. Fig. S1 shows that in CD11c-DTR trans-
genic mice treated with diphtheria toxin, the majority of CD8+ DCs and 
pDCs, and a fraction of mDCs, were depleted and that these cell populations 
are critical for spontaneous CD8+ T cell priming to tumor-associated anti-
gens. Fig. S2 shows that CD8+ DCs fail to accumulate in the tumors grown 
in Stat1/ mice. Fig. S3 shows that parental and SIY-expressing B16 mela-
nomas grow faster in Batf3/ and IFN-/R/ mice compared with 
wild-type. Table S1 shows selected immune-related genes up-regulated with 
B16 tumors, including a panel of IFN-inducible genes. Table S2 shows that 
there is no difference in surface expression levels of CD40, CD80, and 
CD86 in CD11c+ tumor-draining lymph node cells from WT and IFN-/ 
R/ mice. Online supplemental material is available at http://www.jem 
.org/cgi/content/full/jem.20101159/DC1.
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